Prognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosis
© 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology..
Assess the contribution of preoperative MRI data in improving grading of adult astrocytomas reclassified according to the WHO 2016 and cIMPACT-NOW update 3. Retrospective unicentric cohort study of 679 adult patients treated for newly diagnosed diffuse astrocytic and oligodendroglial tumors (January 2006-December 2016). We first systematically compared radiological (contrast enhancement present [CE+] vs. absent [CE-]) and histopathological findings (microvascular proliferation present [MPV+] vs. absent [MPV-]) to validate whether this comparing step of neoangiogenesis represents an efficient method to appreciate the representativity of the tumoral sampling. We focused on 629 cases of astrocytomas for radio-histological integrated analyses. In 598 cases (95.1%), neoangiogenesis evaluated by MRI or histology (CE+/MPV+ or CE-/MPV-) was identical. For the CE+/MPV- and CE-/MPV+ groups (23 cases), the radio-histological face-to-face evaluation allowed us to assess that for 13 cases (56.5%) the reason for this discrepancy was an undersampled tumor. We analyzed the group of CE+/MPV- (n = 8) and CE-/MPV+ (n = 2) in verified image-guided tumoral samples. Finally, we identified three new prognostic subgroups for molecular glioblastomas: (1) "non-representative sampling" (n = 9), (2) "Non neoangiogenic glioblastoma at the time of diagnosis, without contrast enhancement and microvascular proliferation" (n = 8), and (3) "contrast enhancing glioblastoma but without microvascular proliferation in a representative sample" (n = 4). Neoangiogenesis processes should be assessed to improve the prognosis accuracy of the current integrated diagnosis. We suggest adding imaging analyses during the neuropathological analysis of astrocytomas in adults.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Brain pathology (Zurich, Switzerland) - 31(2021), 4 vom: 15. Juli, Seite e12929 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Roux, Alexandre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Astrocytoma |
|---|
| Anmerkungen: |
Date Completed 02.02.2022 Date Revised 02.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bpa.12929 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31901343X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31901343X | ||
| 003 | DE-627 | ||
| 005 | 20231225170547.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bpa.12929 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM31901343X | ||
| 035 | |a (NLM)33336392 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Roux, Alexandre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2022 | ||
| 500 | |a Date Revised 02.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology. | ||
| 520 | |a Assess the contribution of preoperative MRI data in improving grading of adult astrocytomas reclassified according to the WHO 2016 and cIMPACT-NOW update 3. Retrospective unicentric cohort study of 679 adult patients treated for newly diagnosed diffuse astrocytic and oligodendroglial tumors (January 2006-December 2016). We first systematically compared radiological (contrast enhancement present [CE+] vs. absent [CE-]) and histopathological findings (microvascular proliferation present [MPV+] vs. absent [MPV-]) to validate whether this comparing step of neoangiogenesis represents an efficient method to appreciate the representativity of the tumoral sampling. We focused on 629 cases of astrocytomas for radio-histological integrated analyses. In 598 cases (95.1%), neoangiogenesis evaluated by MRI or histology (CE+/MPV+ or CE-/MPV-) was identical. For the CE+/MPV- and CE-/MPV+ groups (23 cases), the radio-histological face-to-face evaluation allowed us to assess that for 13 cases (56.5%) the reason for this discrepancy was an undersampled tumor. We analyzed the group of CE+/MPV- (n = 8) and CE-/MPV+ (n = 2) in verified image-guided tumoral samples. Finally, we identified three new prognostic subgroups for molecular glioblastomas: (1) "non-representative sampling" (n = 9), (2) "Non neoangiogenic glioblastoma at the time of diagnosis, without contrast enhancement and microvascular proliferation" (n = 8), and (3) "contrast enhancing glioblastoma but without microvascular proliferation in a representative sample" (n = 4). Neoangiogenesis processes should be assessed to improve the prognosis accuracy of the current integrated diagnosis. We suggest adding imaging analyses during the neuropathological analysis of astrocytomas in adults | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a WHO classification of CNS tumors | |
| 650 | 4 | |a astrocytoma | |
| 650 | 4 | |a histo-molecular | |
| 650 | 4 | |a imaging | |
| 650 | 4 | |a integrated diagnostics | |
| 700 | 1 | |a Tran, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Edjlali, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Saffroy, Raphaël |e verfasserin |4 aut | |
| 700 | 1 | |a Tauziede-Espariat, Arnault |e verfasserin |4 aut | |
| 700 | 1 | |a Zanello, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Gareton, Albane |e verfasserin |4 aut | |
| 700 | 1 | |a Dezamis, Edouard |e verfasserin |4 aut | |
| 700 | 1 | |a Dhermain, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Chretien, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Lechapt-Zalcman, Emmanuèle |e verfasserin |4 aut | |
| 700 | 1 | |a Oppenheim, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Pallud, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Varlet, Pascale |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain pathology (Zurich, Switzerland) |d 1997 |g 31(2021), 4 vom: 15. Juli, Seite e12929 |w (DE-627)NLM013232258 |x 1750-3639 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:4 |g day:15 |g month:07 |g pages:e12929 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bpa.12929 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 4 |b 15 |c 07 |h e12929 | ||